Therapeutic Asset Ratings

Cilta-Cel

Ibrutinib

Inno-206

Milvexian

(+)-VINCRISTINE

Cetrelimab

Fludarabine

Talquetamab

Jnj-79635322

PEGASPARGASE

PEGASPARGASE

Niraparib

Cetrelimab

Amivantamab-Vmjw

Ramantamig

Amivantamab-Vmjw

AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC)-DERIVED T LYMPHOCYTES TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODINGA CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING TWO EPITOPES OF THE HUMAN B CELL MATURATION ANTIGEN (BCMA) UNDER THE CONTROL OF A HUMAN ELONGATION FACTOR 1 ALPHA (EF1.ALPHA.) PROMOTER THE CODING SEQUENCE COMPRISES A HUMAN CD8 ALPHA SIGNAL PEPTIDE (CD8.ALPHA. SP), A BCMA TARGETING DOMAIN CONSISTING OF TWO VARIABLE HEAVY CHAIN-ONLY ANTIBODIES (VHH1 AND VHH2) TARGETING TWO DISTINCT BCMA EPITOPES, A HUMAN CD8 ALPHA HINGE AND TRANSMEMBRANE DOMAIN (CD8.ALPHA. HINGE + TM), A HUMAN CD137 CYTOPLASMIC DOMAIN (4-1BB) AND A HUMAN CD3 ZETA CYTOPLASMIC DOMAIN (CD3.ZETA.). THE VECTOR GENOME CONTAINS A CHIMERIC ROUS SARCOMA VIRUS (RSV)/TRUNCATED 5'LTR AND A SELF-INACTIVATING 3'LTR-SIN (.DELTA.-U3)

Jnj-89495120

Arestin

((3AR,6AS)-5-(4,6-DIMETHYLPYRIMIDIN- 2-YL)HEXAHYDROPYRROLO(3,4-C)PYRROL-2(1H)-YL)(2-FLUORO- 6-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE OREXIN RECEPTOR ANTAGONIST

Doxycycline

Aticaprant

Aticaprant

SAFIMALTIB

BETAMETHASONE IMPURITY B